

**Molecular Targets of Cancer Chemotherapy**

Trieste, Italy  
September 26-28, 2005



**Co-chairs**

Enrico Mihich, Kurt Zanker, Giorgio Mustacchi

**Program Committee:**

Enrico Mihich (USA)  
Giorgio Mustacchi (Italy)  
Kenneth Nilsson (Sweden )  
Pier Paolo Pandolfi (USA)  
Claudio Schneider (Italy)  
Kurt Zanker (Germany)

**Under the auspices of**

UICC (Union International Contre le Cancer  
Fritz Bender Foundation- Munich)  
AIOM (Associazione Italiana di Oncologia Medica)  
Regione Friuli Venezia Giulia  
University of Trieste  
Ordine dei Medici e Chirurghi di Trieste  
Azienda per i Servizi Sanitari N° 1 triestina

## **Introduction to the Meeting**

Cancer therapeutics is undergoing major changes entering into an era when development of new drugs will be based on the identification of molecular targets uniquely essential for the survival of the cancer cells. In order to discover new drugs it is essential that increased knowledge is acquired about the molecular characteristics of human tumors and the identification of new targets. This Symposium is focused on the understanding of the molecular mechanisms conditioning the progression and growth of cancer and the clinical relevance of the various topics.

Invited Speakers are outstanding scientists, worldwide opinion leaders from different Countries and the Meeting will provide, an exceptional opportunity for an update at the highest level of different topics involved both in basic and clinical aspects of molecular target based therapy of cancer. Each lecture will last 40 minutes and will be followed by a 20 minutes discussion. The format of the meeting will be conducive to cross-stimulation and cross-fertilization among leaders in the topics discussed and in interactions with members of the audience.

Session I should cover genetic and epigenetic mechanisms of control, including methylation and HDAC.

Session II is parallel to Session I but puts some emphasis on biochemical mechanisms.

Session III involves potential targets from receptor to signaling to the nucleus; this session is a continuum with Sessions I and II.

Session IV concerns cellular interactions with its microenvironment including inflammation, cell-matrix and cell-cell interactions, angiogenesis, immunity, etc.

Sessions V and VI are focused on clinical applications. The preceding sessions would also contain translational elements but these sessions would be highly clinical in nature.

Former Annual Symposia have been organized in Bangkok, Beijing, Shanghai, Capetown, Sao Paolo and Salzburg.

## **Meeting Fee**

The Meeting will be reserved to a maximum of 150 participants and registrations will be accepted on "first come first served" basis. Registration fee cover the access to the Meeting, the abstract book and other Meeting materials, coffee breaks and social dinner

Registration fee is € 300, to be paid by bank transfer to the Organizing Secretariat OCT

## **Social Program:**

Social Dinner: Tuesday, September 27<sup>th</sup> .

## **Meeting Venue:**

Trieste, Centro Congressi Stazione Marittima

Well organized Congress Center, former pier for transoceanic ships, in front of the beautiful Piazza Unità, conveniently located near Hotels and shopping area.

## **Organizing Secretariat**

OCT Congressi, Via XX settembre 68, 34100 Trieste Italy

Attn Mrs Patrizia De Colle, e-mail: [patriziadecolle@gmail.com](mailto:patriziadecolle@gmail.com), Ph: 0039 040 53103, fax 0039 040 569924

## **Provider for ECM:**

Patrizia Buzzai, Ufficio Formazione ASS1 N° 1 Triestina

### **Platinum Sponsor**

Novartis Pharma

### **Gold Sponsors**

Eli Lilly; Pfizer , Sanofi-Aventis

### **Other Sponsors**

Amgen, Astrazeneca, Diaco, Eurospital, Glaxo, illycaffè , Ipsen, Roche, Pierre Fabre Pharma, Schering.Plough, Zeneus Pharma

## Meeting Program

**Monday, September 26**

8:00 Registration

8:30 G. Mustacchi, E. Mihich

Welcome, Focus & Goals

### **AM, Session I, Genetic and epigenetic mechanisms of cancer cells regulation**

Moderators: Francisco Baralle, Kirsten Lang

9:00 John Cowell: Approaches For High Throughput Detection Of Molecular Events In Cancer

10:00 Stephen Baylin: The potential for reversing aberrant gene silencing in cancer - where would it affect tumor progression?

**11:00 Coffee Break**

11:30 Peter Jones: Epigenetic Therapy

12:30 Joern Walter: DNA methylation reprogramming in development and disease

**13:30 Lunch**

### **PM, Session II, Molecular nuclear controls**

Moderators: Guido Alberto Manfioletti, Ken Nilsson

15:00 Frank Rauscher: Regulating Gene Expression via Histone Modification: Roles in Development and Disease

**16:00 Coffee Break**

16:30 J.Wade Harper: Signaling via phosphorylation-dependent protein degradation

17:30 David Goodrich: Transcriptional elongation, RNA processing and the Rb tumor suppressor pathway

**18:30 Adjourn**

**Tuesday, September 27**

### **AM, Session III, Signal transduction pathways**

Moderators: Caio Brancolini, Kurt Zanker

8:30 Michael Brattain: Kinase targeting of colon cancer

9:30 Dorian Fabbro: 20 years of protein kinase inhibitors: lessons learned

**10:30 Coffee Break**

11:00 Kenneth Nilsson: Targeting the Insulin-like Growth factor-I receptor Receptor (IGF-IR). Signaling Pathway in Multiple Myeloma

12:00 Frank Entschladen: Pathways leading to a path

**13:00 Lunch**

**PM, Session IV, Cell environment: Interactions**

Moderators: Giannino Del Sal, Enrico Mihich

14:30 Douglas Hanahan: Multi-targeting the constituent cell types mediating tumor angiogenesis

**15:30Coffee Break**

16:00Peter Krammer: CD95(APO-1/FAS) Signalling and Diseases

17:00 Alberto Mantovani: Smouldering And Polarized Inflammation In The Initiation And Promotion Of Malignant Disease

**18:00Adjourn**

**Wednesday, September 28**

**AM, Session V, Clinical strategies I**

Moderators: Gianni Sava, Stephen Baylin

8:30 Antonio Amoroso: Genetic counselling and testing for inherited cancer

9:30 Sylvie Menard: HER2 as a specific target for therapy

**10:30Coffee Break**

11:00 Donald Small: Prognostic and therapeutic implication of FLT3 mutations in leukemia

12:00 Romano Danesi: Pharmacogenetic strategies for clinical development of target-specific anticancer agents

**13:00Lunch**

**PM, Session VI, Clinical strategies II**

Moderators: Giorgio Mustacchi, TBA

14:30 Pier Giuseppe Pelicci: HDAC inhibitors in the treatment of leukemias

**15:30Coffee Break**

16:00 Jean-Pierre Issa Epigenetic Therapy of Cancer: Clinical and Molecular Results

17:00Federico Calligaris Cappio Chronic Lymphocytic Leukemia: a model to develop new clinical strategies for indolent lymphoid malignancies.

**18:00Kurt Zanker: Concluding Remarks**

**18:30 - 19:30  
Symposium Evaluation for ECM**

## Faculty

Amoroso, Antonio	University of Trieste Medical Genetics Service, Trieste, Italy
Baralle, Francisco	Intl Centre for Genetic Engineering & Biotechnology AREA Science Park, Trieste, Italy
Baylin, Stephen	Johns Hopkins Comprehensive Cancer Ctr Baltimore, USA
Brancolini, Caio	Dipartimento di Scienze e Tecnologie Biomediche, Sezione di Biologia University of Udine, Italy
Brattain, Michael	Roswell Park Cancer Institute Buffalo, USA
Caligaris-Cappio, Federico	Clinical Immunology University of Torino, Italy
Cowell, John	Cancer Genetics Roswell Park Cancer Institute, Buffalo, USA
Danesi, Romano	Div Pharmacology & Chemotherapy University of Pisa, Italy
Del Sal, Giannino	Molecular Oncology Unit. Laboratorio Nazionale CIB Faculty of Biology, University of Trieste, Italy
Entschladen, Frank	Inst of Immunology Univ of Witten/Herdecke, Witten, Germany
Fabbro, Dorian	Novartis Pharma Inc Oncology Novartis, Basel, Switzerland
Goodrich, David	Department of Pharmacology & Therapeutics Roswell Park Cancer Institute, Buffalo, USA
Hanahan, Douglas	Dept Biochem & Biophys University of California, San Francisco, USA
Harper, J Wade	Dept of Biology Harvard Medical School, Boston, USA
Issa, Jean-Pierre	Department of Leukemia MD Anderson Cancer Center, Houston, USA
Jones, Peter	Norris Comp Ca Ctr Univ of Southern California, Los Angeles, USA
Krammer, Peter	German Cancer Research Center Head of Tumorimmunology Program Im Neuenheimer Feld, Heidelberg, Germany
Lang, Kerstin	Inst of Immunology Univ of Witten/Herdecke, Witten, Germany
Manfioletti, Guidalberto	Dipartimento di Biochimica, Biofisica e Chimica delle Macromolecole University of Trieste, Italy
Mantovani, Alberto	Department of Immunology and Cell Biology Istituto di Ricerche Farm Mario Negri, Milano Italy
Menard, Sylvie	Molecular Targeting Unit of the Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
Mihich, Enrico	Department of Pharmacology & Therapeutics Roswell Park Cancer Inst, Buffalo, USA
Mustacchi, Giorgio	Medical Oncology University of Trieste, Italy
Nilsson, Kenneth	Dept of Genetics & Pathology Uppsala Univ Hosp, Rudbeck Laboratory, Uppsala, Sweden
Pandolfi, Pier Paolo	Memorial Sloan Kettering Cancer Ctr New York, USA
Pellicci, Pier Giuseppe	European Institute of Oncology Div of Exper Oncology I, Milan, Italy
Rauscher, Frank	Wistar Institute Philadelphia, USA
Sava, Gianni	Department of Biomedical Sciences University of Trieste, Italy
Schneider, Claudio	Area Science Park Trieste, Italy
Small, Donald	Sidney Kimmel Comprehensive Cancer Str Johns Hopkins, Baltimore, USA
Walter, Jörn	Saarland University Dept Genetics/Epigenetics, Saarbrücken, Germany
Zanker, Kurt	Inst of Immunology Univ of Witten/Herdecke, Witten, Germany